After a horrendous start of Paytm, we are again cautioning investors on Pharmeasy. Pharmeasy Consolidated Results (including all subsidiaries) as per March,2021Total Revenue =&gt; ₹4,363.2 cr&nbsp;Total Consolidated Loss (including all subsidiaries) =&gt; ₹1,548.5 crTotal Debt on 30th June,2021 =&gt; ₹2,772.61 cr This means on every 1 cr sale of medicine, lab tests (including all subsidiaries), company incur a loss of 35.49 Lacs. People should be cautious while investing in Pharmeasy stocks at such steep valuations or exit before the stock crashes.

After a horrendous start of Paytm, we are again cautioning investors on Pharmeasy. People should be cautious while investing in Pharmeasy stocks.